Thyroid Cancer

OR44-1

Three-Year Results and Future Scope of the Fukushima Thyroid Ultrasound Examination after the Fukushima Nuclear Power Plant Accident
Shinichi Suzuki, Satoru Suzuki, Toshihiko Fukushima, Izumi Nakamura, Hiroki Shimura, Sanae Midorikawa, Tetsuya Ohira and Shunichi Yamashita

OR44-2

The Variable Phenotype and Low-Risk Nature of RAS-Positive Thyroid Nodules
Norra Kwong, Marco Medici, Trevor E Angell, Ellen Marqusee, Matthew Ian Kim, Mary C Frates, Carol B Benson, Edmund S Cibas, Justine Barletta, Jeffery F Krane, Daniel T Ruan, Nancy L. Cho, Atul Gawande, Francis D. Moore and Erik Karl Alexander

OR44-3

Lysyl Oxidase (LOX) Regulates Slug Expression in Anaplastic Thyroid Cancer
Myriem Boufraqech, Sudheer Kumar Gara, Naris Nilubol, Lisa Zhang, Martha M Quezado and Electron Kebebew

OR44-4

Salvage Therapy: When a Tyrosine Kinase Inhibitor (TKI) Fails in Advanced Medullary Thyroid Cancer (MTC)
Steven P Weitzman, Katherine T. Peicher, Ramona Dadu, Mimi I-Nan Hu, Camilo Jimenez, Carly Gardner, Aliya Qayyum, Mike Hernandez and Maria E Cabanillas

OR44-5

Phase II Clinical Trial of Sunitinib As Adjunctive Treatment in Patients with Advanced Differentiated Thyroid Cancer
Athanasios Bikas, Priya Kundra, Jason Adam Wexler, Mihriye Mete, Sameer Desale, Lynette Wray, Christina Barett, Brandon Clark, Leonard Wartofsky and Kenneth Burman

OR44-6

Open-Label Extension Phase Outcomes of the Phase 3 Select Trial of Lenvatinib in Patients with 131I-Refractory Differentiated Thyroid Cancer
Bruce Gregory Robinson, Martin Schlumberger, Steven I Sherman, Makoto Tahara, Lori Wirth, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Corina E Dutcus, Junming Zhu and Kate Newbold